CurrentAetnaPolicy 0471

Tuberculosis Testing

Customize your policy alerts

Sign up for Aetna Policy 0471 alerts

Get alerted when Policy 0471 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Clinical policy governing medical necessity, coverage, and coding for tuberculosis (TB) testing methods (Mantoux TST, QuantiFERON/QFT-G, T-SPOT, rapid molecular tests, and select urine antigen testing) for Aetna members.

Policy Summary

PayerAetna

PolicyTuberculosis Testing

Policy CodePolicy 0471

Change TypeNo material change

Effective DateApr 13, 2001

Last ReviewFeb 16, 2024

Next Review DateMay 9, 2024

Key ActionDocument the clinical indication aligning with selection criteria to support medical necessity for TB testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

TST, QFT, T-SPOTPrimary tests considered medically necessary

Rapid molecular testsMedically necessary for MDR-TB detection

FujiLAMMedically necessary for TB diagnosis in HIV

Tine, breath, stool molecularConsidered experimental / investigational

CPT/HCPCS/ICD-10 listsCoding included

02/16/2024Last review

Coverage and Medical Necessity Criteria

Medical necessity — who to screen

Covered when ANY one of the following selection criteria is met:

Screening indication groups: 1. Suspected active TB; 2. Close contacts of persons known or suspected to have TB (those sharing household or enclosed environments); 3. Foreign‑born persons, including children, recently arrived (within 5 years) from countries with high TB incidence or prevalence (e.g., Africa, Asia, Latin America, Middle East, Oceania, Caribbean); 4. Health‑care workers who serve high‑risk clients; 5. High‑risk racial or ethnic minority populations as defined locally; 6. Individuals planning to receive or receiving tumor necrosis factor (TNF)‑alpha inhibitors (e.g., infliximab); 7. Infants, children, and adolescents exposed to adults in high‑risk categories; 8. Persons who inject illicit drugs or other locally identified high‑risk substance users; 9. Residents and employees of high‑risk congregate settings (e.g., correctional institutions, mental institutions, nursing homes, other long‑term residential facilities, and shelters for the homeless); 10. Some medically under‑served, low‑income populations; 11. Persons with any of the listed medical risk factors that increase risk for progression if infected (e.g., chronic renal failure; prolonged high‑dose corticosteroid or other immunosuppressive therapy including transplantation; diabetes mellitus; gastrectomy; HIV infection; jejuno‑ileal bypass; certain malignancies; abnormal chest radiograph with fibrotic lesions consistent with old/healed TB; silicosis; hematological disorders such as leukemias/lymphomas; weight ≥10% below ideal).

Any single item qualifies the member for screening per policy.

Interferon-gamma assay coverage criteria

Covered uses for QFT/QFT‑G/T‑SPOT when criteria met:

QFT/QFT‑G/T‑SPOT acceptable uses: 1. Initial and serial testing of persons with increased risk for latent TB infection (LTBI) (e.g., injection‑drug users, recent immigrants, residents and employees of prisons and jails); OR 2. Initial and serial testing of persons who by history are low‑risk but whose future activity may increase exposure risk and others in surveillance programs (e.g., health‑care workers, military personnel); OR 3. Testing of persons for whom LTBI screening is performed though not considered increased probability (e.g., entrance requirements for certain schools and workplaces).

QuantiFERON‑TB Gold (QFT‑G) can be used in place of (not in addition to) the Mantoux TST per CDC guidance; utility of QFT to predict progression to active TB is not established.

Molecular testing / FujiLAM

Covered when applied to the indicated clinical scenarios:

Rapid molecular and urine LAM: 1. Rapid molecular testing (e.g., GeneXpert MTB/RIF, MTBDRplus, MTBDRs) is medically necessary for detection of multi‑drug resistant TB; OR 2. Urine‑based lipoarabinomannan antigen testing (FujiLAM) is medically necessary for diagnosis of TB in individuals with HIV.

Specific CPT coding may vary; refer to coding section for covered codes.

Experimental / Investigational

Not covered when used for the following:

Experimental or investigational tests: Biomarker‑based non‑sputum tests for TB diagnosis; breath tests (electronic‑nose); molecular stool tests (e.g., stool Xpert MTB/RIF and TruTip workstation) for detection of pulmonary TB in children; multiple‑puncture TB skin tests (tine tests); whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance.

These are considered experimental/investigational due to insufficient evidence supporting effectiveness.

Clinical-use criteria and evidence summaries

Screening prior to anti‑TNF or systemic immunosuppressive therapy: Screen all patients for LTBI prior to initiating immunologic or anti‑TNF therapy; delay immunologic therapy until LTBI prophylaxis is completed when feasible. If prophylaxis is in progress and tolerated, initiation of immunologic therapy may be considered after 1–2 months if clinically required.

Screening and treatment reduce but do not eliminate TB risk; follow consensus guidance.

Interpreting IGRAs in serial testing (health‑care workers): Recognize higher within‑subject variability with IGRAs, with more reversions than conversions; consider a borderline QFT zone (0.2–0.7 IU/mL) and retest borderline results (approximately within 4 weeks) or assess clinical risk before initiating preventive therapy.QFT 0.2–0.7 IU/ml borderline

Document quantitative values and clinical assessment when interpreting serial IGRA results.

Use of IGRAs vs TST for predicting progression: Neither IGRAs nor TSTs have high predictive accuracy for progression to active TB; pooled incidence rate ratio for IGRA‑positive versus IGRA‑negative individuals is moderate (~2.10). Choose testing modality considering specificity, logistics, cost, and patient factors.

Absolute incidence among IGRA‑positives remains low in longitudinal studies.

Rapid molecular testing for drug resistance: Rapid molecular assays (e.g., GeneXpert MTB/RIF, MTBDRplus, INNO‑LiPA) detect rifampicin and/or isoniazid resistance rapidly with high pooled sensitivity and specificity; positive rifampicin‑resistance results should be confirmed by sequencing and followed by growth‑based drug susceptibility testing (DST).

Models indicate adding rapid assays to culture/DST is cost‑effective and reduces expected QALY loss.

Stool‑based molecular testing in children: Stool Xpert and other molecular stool assays can be used as non‑invasive rule‑in tests for pediatric pulmonary TB due to high specificity but moderate and heterogeneous sensitivity; sensitivity is higher in HIV‑infected and smear‑positive children; standardized stool processing protocols are lacking and data in children <5 years are limited.sensitivity ~57–67% and specificity ~97–99% in pooled analyses

Consider as adjunctive diagnostic approach where sputum sampling is difficult.

Diagnostic performance and contexts for non-sputum and advanced molecular TB tests

Evidence‑based diagnostic performance summaries present conditions where molecular non‑sputum or advanced molecular tests may be useful:

Stool molecular testing (children): Stool Xpert and other stool molecular assays exhibit high specificity but moderate sensitivity for pediatric pulmonary TB; pooled sensitivity ranges approximately 57–67% with specificity around 97–99%; sensitivity is higher in HIV‑infected and smear‑positive children.sensitivity ~57–67% / specificity ~97–99%

Heterogeneity and lack of standardized stool processing limit generalizability; data sparse for children <5 years.

TruTip stool workstation: In a Peruvian pediatric cohort, TruTip extraction with IS6110 PCR showed sensitivity ~59% and specificity ~97%; detection was associated with smear positivity, older age, sputum production, and cavitary disease.sensitivity 59%, specificity 97%

Low sensitivity in clinically diagnosed unconfirmed TB; further optimization needed.

Breath tests (electronic‑nose): Electronic‑nose devices have shown variable but sometimes high pooled sensitivity and specificity in preliminary studies (e.g., ~0.93/0.93 in some reports); current evidence is limited by small studies and lack of external validation.pooled sensitivity/specificity variable (some reports ~93%)

Promising for screening or rule‑out pending larger validation studies.

Xpert Ultra (adults, pulmonary): Xpert Ultra demonstrates higher pooled sensitivity (~90.9%) but slightly lower pooled specificity (~95.6%) compared with Xpert MTB/RIF (sensitivity ~84.7%, specificity ~98.4%) for pulmonary TB in adults; gains are larger in smear‑negative and HIV‑positive subgroups with more trace‑positive results observed.sensitivity 90.9%, specificity 95.6%

Trade‑off: fewer missed cases but more false positives versus Xpert MTB/RIF; consider setting and patient population when selecting assay.

Xpert Ultra (pleural TB): In pleural fluid, Xpert Ultra showed higher sensitivity than culture, Xpert, and smear in a cited cohort (Xpert Ultra sensitivity 44.2% vs culture 26.4% and Xpert 19.2%) while maintaining high specificity (~98.7%).sensitivity Xpert Ultra 44.2% vs culture 26.4% and Xpert 19.2%

May increase proportion of definite pleural TB diagnoses when added to diagnostic workup.

Evidence summaries / clinical performance

Evidence summaries and subgroup findings for test performance (no explicit payer coverage criteria in this section):

Xpert Ultra vs Xpert MTB/RIF overall pulmonary TB accuracy: Meta‑analyses show Xpert Ultra pooled sensitivity ~90.9% and specificity ~95.6% versus Xpert MTB/RIF pooled sensitivity ~84.7% and specificity ~98.4%; Ultra misses fewer TB cases but yields more false positives than MTB/RIF in some settings.

Absolute trade‑offs depend on TB prevalence and subgroup characteristics.

Smear‑negative and HIV‑positive subgroups: In smear‑negative, culture‑positive participants Ultra sensitivity ~77.5% versus MTB/RIF ~60.6%; in people living with HIV Ultra sensitivity ~87.6% versus MTB/RIF ~74.9%; Ultra specificity is lower in these subgroups compared with MTB/RIF.

Important for test selection in smear‑negative and HIV‑positive patients.

Rifampicin resistance detection: Xpert Ultra and Xpert MTB/RIF have similar sensitivity and specificity for rifampicin resistance detection overall, though Ultra yields a higher pooled proportion of indeterminate rifampicin‑resistance results (~7.6% vs ~0.8% for MTB/RIF), warranting confirmatory testing for indeterminate results.

Confirm positive or indeterminate resistance findings with sequencing and growth‑based DST.

FujiLAM performance in HIV‑positive adults: FujiLAM demonstrates sensitivity approximately 60–69% and specificity roughly 87–92% against microbiological reference standards in adults living with HIV; sensitivity is higher among those with lower CD4 counts and varies by lot number.

WHO recommends use of LAM assays in HIV‑infected individuals with signs/symptoms of TB or who are seriously ill or have CD4 <100 cells/mm3.

FujiLAM in children and HIV‑negative children: In pediatric studies FujiLAM sensitivity varied (approximately 42–60% in reported cohorts) with higher specificity (around 90–96%); FujiLAM may serve as a rule‑in test in hospitalized children with high pre‑test probability (e.g., HIV, malnutrition), but additional large studies are needed.

Lot‑to‑lot variability and study limitations affect interpretation of pediatric accuracy estimates.

Coverage of TB testing may be affected by member-specific benefit language. Some Aetna plans exclude services required solely for third parties (for example, employment, travel, or school), and some plans exclude preventive services. Verify the member’s benefit plan before ordering tests that are performed to satisfy third‑party requirements or routine screening outside of the medical necessity criteria listed in this policy.

Interferon‑gamma release assays (IGRAs: QFT/QFT‑G/T‑SPOT) may be used in place of the Mantoux TST but are not recommended to be performed routinely in addition to TST for the same screening episode. The CDC notes that PPD injection for a recent TST can affect subsequent QFT results, and QFT is not recommended to confirm recent TST results; QFT may be used for surveillance under limited conditions. When replacing TST with an IGRA, document the clinical indication and follow CDC guidance on timing and interpretation.

Evidence for several novel sample types and technologies is limited by small study numbers, heterogeneous populations, and variable specimen collection and processing methods. For example, stool molecular assays in children show promising specificity but moderate and inconsistent sensitivity across studies, and variability in stool handling and assay protocols reduces generalizability. Readers should interpret diagnostic performance summaries with caution and consider local prevalence, patient mix (including HIV status and age), and methodological heterogeneity when applying study results to practice.

When interpreting Xpert Ultra results, note that specificity is lower in persons with a prior history of tuberculosis compared with those without prior TB. This can increase the proportion of false‑positive Ultra results (including trace‑positive findings) in individuals with previous TB disease and should be considered in clinical interpretation and follow‑up testing decisions.

Multiple puncture (tine) TB skin tests and other unvalidated experimental approaches (e.g., biomarker non‑sputum tests, breath tests, molecular stool tests for routine pediatric diagnosis, and whole genome sequencing for drug‑resistance determination) are identified in this policy as experimental/investigational and are not supported for clinical coverage due to insufficient evidence of effectiveness.

Available tests for latent TB infection (IGRAs and TST) have limited predictive accuracy for progression to active disease. Longitudinal data show only a moderate association between positive IGRA results and subsequent TB (pooled IRR ≈ 2.10), and neither test reliably predicts which individuals will develop active TB. Test selection should therefore consider specificity, logistics, cost, and patient preference rather than expectations of high prognostic performance.

Across several diagnostic areas, study heterogeneity and methodological limitations limit definitive conclusions. Examples include variable stool processing methods for molecular stool assays in children, differing definitions of confirmed versus clinically diagnosed TB, and inconsistent reporting of trace‑positive Xpert Ultra results. These factors contribute to uncertainty about real‑world performance and support cautious adoption pending further standardized, larger studies.

Some sections of the source document summarize evidence and state that particular approaches are experimental or investigational, but do not explicitly label every emerging test as "not medically necessary". Where the policy identifies techniques as experimental/investigational (for example, multiple puncture skin tests or biomarker non‑sputum assays), those uses are not supported; however, absence of an explicit "not medically necessary" statement in a specific evidence summary does not imply coverage — clinical applicability depends on the policy’s stated coverage criteria and member benefits.

Billing and Coding

CPT codes covered if selection criteria are metCPTCovered

86480	Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon.
86481	Enumeration of gamma interferon-producing T-cells in cell suspension.
86580	Skin test; tuberculosis, intradermal [Mantoux].
87556	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria tuberculosis, amplified probe technique [GeneXpert MTB/RIF].
87798	Infectious agent detection by nucleic acid (DNA or RNA), not otherwise specified; amplified probe technique, each organism [GeneXpert MTB/RIF].

CPT codes not covered for indications listed in the CPB (e.g., whole genome sequencing)CPTNot Covered

81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis.
81426	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings( (List separately in addition to code for primary procedure).
81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome).

Other CPT codes related to the CPBCPT

71045-71048	Radiologic examination, chest.
87116	Culture, tubercle or other acid-fast bacilli (e.g., TB, AFB, mycobacterial) any source, with isolation and presumptive identification of isolates.
90585	Bacillus Calmette-Guerin vaccine (BCG) for tuberculosis, live, for percutaneous use.

HCPCS/Drugs related to patients receiving TNF-alpha inhibitorsHCPCS

J0135	Injection, adalimumab, 20 mg.
J1438	Injection, etanercept, 25 mg (code may be used for Medicare when drug administered under the direct supervision of a physician, not for use when drug is self-administered).
J1745	Injection, infliximab, 10 mg.
Q5103	Injection, infliximab-dyyb, biosimilar, (Inflectra), 10 mg.
Q5104	Injection, infliximab-abda, biosimilar, (Renflexis), 10 mg.
Q5109	Injection, infliximab-qbtx, biosimilar, (Ixifi), 10 mg.
Q5131	Injection, adalimumab-aacf (idacio), biosimilar, 20 mg.
Q5132	Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg.
S9359	Home infusion therapy, antitumor necrosis factor intravenous therapy; (e.g., Infliximab); administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits codes separately), per diem.

ICD-10 codes covered if selection criteria are metICD-10Covered

A15.0-A19.9	Tuberculosis.
B20	Human immunodeficiency virus [HIV] disease.
B90.0-B90.9	Sequelae of tuberculosis.
Z11.1	Encounter for screening for respiratory tuberculosis.
Z20.1	Contact with and (suspected) exposure to tuberculosis.
Z68.1	Body mass index [BMI] 19 or less, adult.
Z94.0-Z94.89	Transplanted organ and tissue status.
Z98.0	Intestinal bypass or anastamosis status [jejuno-ileal bypass]

inv-21: TST antigen dose — 5 units PPD (Mantoux)

TST antigen dose5 units purified protein derivative (PPD) via intradermal Mantoux test

Test purposeAssess delayed-type (Type IV) hypersensitivity indicating prior exposure to M. tuberculosis

Multiple-puncture testsTine (multiple puncture) tests are less specific and not recommended for screening high-risk populations

inv-22: QFT borderline zone — 0.2 to 0.7 IU/ml

QFT borderline zoneBorderline (indeterminate) zone defined as 0.2 to 0.7 IU/ml for repeat/serial testing interpretation

Recommended action for borderline resultsRe-test with QFT within ~4 weeks before recommending preventive chemotherapy if recent infection suspected

RationaleAccounts for within-subject variability and higher reversion rates observed around diagnostic threshold

Provider Obligations, Documentation & Authorization

Note

Confirmatory Testing Recommendation

CDC guidance and Aetna policy note that confirmatory testing is recommended when rapid molecular assays (e.g., Xpert MTB/RIF showing rifampin resistance) detect resistance mutations: confirmatory rapid DNA sequencing and growth‑based drug susceptibility testing (DST) should be performed per CDC guidance to guide treatment decisions.

Confirm positive molecular rpoB mutations with rapid sequencing and follow-up growth-based DST per CDC guidance.
Document when confirmatory testing is ordered and results used to direct therapy.

Prior Authorization

Prior Authorization — Not Specified

No prior authorization requirements are specified in the excerpt provided for Xpert/Xpert Ultra, stool Xpert, or FujiLAM testing. Providers should verify member-specific plan benefits and prior authorization rules before ordering.

Prior authorization: not specified in this policy excerpt for molecular (Xpert/Xpert Ultra), stool Xpert, or urine FujiLAM tests.
Check member benefits and plan-specific PA lists before ordering.

Denial Risk

Experimental / Investigational Tests — Denial Risk

The policy lists several tests as experimental/investigational — these are at risk for denial as effectiveness has not been established.

Biomarker-based non-sputum tests (experimental) — denial risk.
Breath tests (electronic-nose) — denial risk.
Molecular stool tests for pediatric pulmonary TB (listed experimental) — denial risk when billed for non-covered indications.
Multiple-puncture tine skin tests — considered less specific; investigational/not covered.
Whole genome sequencing of M. tuberculosis for detection of drug resistance — investigational (denial risk).

Note

Administrative Notes — No Explicit Triggers

This segment of the policy contains administrative notes, links to policy history, and general guidance but does not specify additional provider authorization triggers or step-therapy rules.

No explicit administrative denial triggers are provided in this section.
No step therapy sequencing requirements are described in this excerpt.

Documentation Required

Required Clinical Documentation

Providers must document clinical indications that align with the policy selection criteria when ordering TB tests (e.g., suspected active TB, contact investigation, immigration screening, HIV status, immunosuppression, planned TNF‑alpha inhibitor therapy).

Document clinical indication matching selection criteria (suspected active TB, close contact, recent immigrant from high-incidence area, health-care worker surveillance, pre‑TNF‑alpha inhibitor screening, HIV status, etc.).
For urine LAM testing, document HIV status, clinical signs/symptoms, and CD4 count when applicable per WHO/CDC context.

Documentation Required

Documentation for IGRA Serial Testing

For serial/intermittent IGRA testing (e.g., health‑care worker surveillance), document the clinical assessment and interpret quantitative IGRA values, especially when values are near the assay cut-off; record prior results, timing of tests, and rationale for treating converters versus reverters.

Record baseline and serial IGRA quantitative values and dates.
Document clinical assessment when interpreting conversions/reversions and when considering treatment.
Note that QFT-G is intended to replace, not be added to, the Mantoux TST per CDC guidance; document which test is used.

Clinical Background

Tuberculosis is caused by organisms in the Mycobacterium tuberculosis complex and is primarily transmitted via airborne spread. Most infected persons have latent infection without symptoms but remain at risk for progression to active disease if immunity declines. The Mantoux TST (intradermal 5 units PPD) and interferon‑gamma release assays (QFT/QFT‑G/T‑SPOT) are the primary screening tools; IGRAs measure in‑vitro interferon‑gamma responses and may offer advantages in specificity and single‑visit testing, particularly for BCG‑vaccinated individuals.

Test Definitions and Terms

inv-44: Mantoux tuberculin skin test (TST) — intradermal 5 units PPD

AdministrationIntradermal administration of 5 units purified protein derivative (PPD) — Mantoux test

MechanismAssesses in-vivo delayed-type hypersensitivity (Type IV) response to PPD

Clinical noteTine/multiple-puncture tests should not be used for screening high-risk populations due to lower specificity

inv-45: QuantiFERON-TB Gold (QFT-G) / QFT — interferon-gamma release assay definition

DefinitionIn-vitro cytokine-based immunoassay measuring interferon-gamma release in response to M. tuberculosis-specific antigens (e.g., QuantiFERON/T-SPOT)

Intended useCan be used in place of (not in addition to) the TST for contact investigations, screening of health-care workers, and evaluation of recent immigrants

AdvantagesNot affected by prior BCG vaccination and does not cause boosting of subsequent skin tests

inv-46: Rapid molecular tests (GeneXpert MTB/RIF) — NAAT for MTB and rifampin resistance

DefinitionNucleic acid amplification tests (NAATs) that detect Mycobacterium tuberculosis and mutations associated with rifampin/isoniazid resistance (e.g., GeneXpert MTB/RIF, MTBDRplus)

Clinical roleConsidered medically necessary for detection of multi‑drug resistant TB and to speed diagnosis and control of MDR-TB

LimitationsIdentify primarily rifampin and/or isoniazid resistance; confirmatory sequencing and growth-based DST recommended for resistance findings

inv-47: TNF-alpha inhibitors — biologic agents increasing TB reactivation risk

Class descriptionBiologic agents (e.g., infliximab and other anti–TNF-alpha therapies) used to treat inflammatory disorders

TB riskThese agents increase risk of TB reactivation (reported 4- to 20-fold with infliximab); screening and treatment of LTBI before therapy reduces but does not eliminate risk

Clinical recommendationScreen all patients for LTBI prior to initiating anti‑TNF or other immunosuppressive biologic therapies; delay therapy until prophylaxis completed when feasible

inv-48: Xpert MTB/RIF — rapid molecular assay description and CDC recommendation context

Test descriptionXpert MTB/RIF is a rapid cartridge-based NAAT that detects M. tuberculosis complex and mutations in rpoB associated with rifampin resistance

CDC contextCDC recommends confirmatory rapid DNA sequencing and follow-up growth‑based DST for RMP-resistance findings due to low prevalence of RMP-resistance in the U.S.

Performance notePer evidence, Xpert provides faster results than culture but may have limitations detecting all rifampin-resistant isolates

inv-49: Whole genome sequencing (WGS) — sequencing for drug-resistance prediction

DefinitionWhole genome sequencing (WGS) of M. tuberculosis to predict drug-resistance profiles by identifying genetic variants associated with resistance

PerformanceWGS shows high concordance with phenotypic DST for rifampicin and isoniazid in some studies (pooled sensitivity/specificity high) but requires standardization

LimitationAnalytical pipelines, heterogeneity, and gaps in knowledge of resistance mechanisms limit routine clinical use pending further validation

inv-50: Xpert MTB/RIF — automated NAAT that outperforms smear in some contexts

DescriptionAutomated nucleic acid amplification assay (Xpert MTB/RIF) that detects M. tuberculosis and rifampin resistance and generally outperforms smear microscopy in detection

Clinical utilityPer UpToDate and studies, Xpert offers rapid results (median ~1 day) and improved detection over smear, with utility in pediatric specimens when multiple samples tested

LimitationsDetection of rifampin resistance can have indeterminate results; additional confirmatory testing is advised

inv-51: Xpert MTB/RIF Ultra (Xpert Ultra) — next-generation cartridge assay with greater sensitivity

Test descriptionXpert MTB/RIF Ultra (Xpert Ultra) is a next‑generation cartridge assay with increased analytic sensitivity for M. tuberculosis and rifampin resistance

Performance trade-offUltra has higher pooled sensitivity but somewhat lower pooled specificity versus Xpert MTB/RIF, with greater gains in smear‑negative and HIV‑positive populations

Clinical implicationUltra reduces missed cases but increases false-positives (including more trace-positive and indeterminate RIF‑resistance results); selection should consider setting and pretest probability

inv-52: stool Xpert — use of Xpert on stool specimens for pediatric pulmonary TB diagnosis

DefinitionApplication of the Xpert MTB/RIF assay to stool specimens as a non‑invasive diagnostic option to detect pulmonary TB in children

Performance summaryPooled sensitivity ~57–67% and specificity ~97–99% versus microbiologic reference; higher sensitivity in HIV‑positive and smear‑positive children

LimitationsHeterogeneous stool processing protocols and limited data in children <5 years; standardization needed

inv-53: electronic-nose (eNose) — breath-test device for volatile organic compounds

DefinitionElectronic‑nose (eNose) is a breath‑test device that detects volatile organic compounds to distinguish TB from non‑TB states

Evidence statusMeta-analysis reported high pooled sensitivity and specificity in small studies but overall evidence is low-to-moderate and variable

Policy stanceConsidered experimental/investigational pending further development and larger validation studies

inv-54: Xpert Ultra — cartridge-based molecular assay with higher sensitivity but lower specificity in some populations

Assay characteristicsXpert Ultra is a cartridge‑based molecular assay with higher sensitivity but lower specificity versus Xpert MTB/RIF in some populations

Performance metricsPooled sensitivity ~90.9% and specificity ~95.6% for pulmonary TB in adults versus culture (meta-analysis)

Clinical trade-offGreater sensitivity yields fewer missed cases but increases false-positives; particularly relevant in smear‑negative and HIV‑positive subgroups

inv-55: Xpert MTB/RIF — earlier cartridge-based molecular assay with generally higher specificity in some subgroups

Assay descriptionXpert MTB/RIF is an earlier cartridge‑based molecular NAAT that detects M. tuberculosis and rifampin resistance

Specificity noteXpert MTB/RIF generally shows higher specificity than Xpert Ultra in some subgroups (e.g., individuals with prior TB history)

Clinical contextUsed widely as a rapid diagnostic; confirmatory growth‑based DST advised for resistance findings

inv-56: FujiLAM — Fujifilm SILVAMP TB LAM urine antigen test with improved sensitivity over AlereLAM in HIV-positive patients and children

Test nameFujifilm SILVAMP TB LAM (FujiLAM) — urine lipoarabinomannan antigen test

Performance in HIV-positive adultsImproved sensitivity (~60%) and specificity (~87–92%) versus AlereLAM; higher sensitivity in patients with low CD4 counts

Pediatric findingsIn children, FujiLAM sensitivity varied (e.g., ~42–60%), with higher sensitivity in HIV‑positive and malnourished children and higher specificity than AlereLAM

Policy Dates & Revision Notes

2024-02-16policy_reviewLatest

Policy was last reviewed on 02/16/2024; administrative policy history entry recorded.

2001-04-13effective_date

Policy effective date established as 04/13/2001.

2024-05-09next_review_scheduled

Next scheduled policy review set for 05/09/2024.

Policy Summary

PayerAetna

PolicyTuberculosis Testing

Policy CodePolicy 0471

Change TypeNo material change

Effective DateApr 13, 2001

Last ReviewFeb 16, 2024

Next Review DateMay 9, 2024

Key ActionDocument the clinical indication aligning with selection criteria to support medical necessity for TB testing.

SourceLink

On This Page

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.